Will Aducanumab Join List Of Drugs Approved By US FDA Over Advisory Committee Opposition?

 
• By Brenda Sandburg

A look at drugs the agency approved despite an advisory committee vote not to do so and how they compare to Biogen’s Alzheimer’s disease drug aducanumab.

Two men change their common route taking different ways
FDA has previously parted ways with an advisory committee in approving a drug • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers